Unlike EGFR-mediated activation, mutant p53 promotes PKM2 tetramerization, which in turn drives H3-T11 phosphorylation, inhibits HDAC3 binding, stabilizes H3-K9 acetylation, and introduces K9 methylation—ultimately activating telomerase and promoting tumor growth. Here, PKM is linked to neoplasm.